Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05846646 · ClinicalTrials.gov registry record · Phase 2
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
A Phase 2 study, sponsored by ImmuneSensor Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT05846646 is a Phase 2 study that was terminated before completion, run by ImmuneSensor Therapeutics. The registered enrollment target is 6 participants.
The verdict
NCT05846646, a Phase 2 study, was terminated before completion, sponsored by ImmuneSensor Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC
Interventions
- DRUG IMSA101
- DRUG Immune checkpoint inhibitor
- RADIATION PULSAR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2024-09-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05846646
The ClinicalTrials.gov registry entry for NCT05846646 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmuneSensor Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IMSA101 is the first listed.
NCT05846646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05846646 about?
NCT05846646 is a clinical study titled "Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC". Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy (PULSAR-ICI) + IMSA101 and PULSAR-ICI alone in patients with NSCLC or RCC
What is the current status of trial NCT05846646?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2023-06-28. Estimated completion is 2024-09-16.
What interventions are being tested in trial NCT05846646?
The interventions under investigation include: IMSA101 (DRUG), Immune checkpoint inhibitor (DRUG), PULSAR (RADIATION).
Who is sponsoring clinical trial NCT05846646?
This trial is sponsored by ImmuneSensor Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.